KR20180051095A - Diet beverage comprising white grup and preparation method thereof - Google Patents
Diet beverage comprising white grup and preparation method thereof Download PDFInfo
- Publication number
- KR20180051095A KR20180051095A KR1020160147988A KR20160147988A KR20180051095A KR 20180051095 A KR20180051095 A KR 20180051095A KR 1020160147988 A KR1020160147988 A KR 1020160147988A KR 20160147988 A KR20160147988 A KR 20160147988A KR 20180051095 A KR20180051095 A KR 20180051095A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- weight
- mixed
- cholesterol
- comparative example
- Prior art date
Links
- 235000005911 diet Nutrition 0.000 title claims abstract description 54
- 230000037213 diet Effects 0.000 title claims abstract description 48
- 235000013361 beverage Nutrition 0.000 title abstract description 9
- 238000002360 preparation method Methods 0.000 title description 28
- 239000000284 extract Substances 0.000 claims abstract description 113
- 229920001661 Chitosan Polymers 0.000 claims abstract description 37
- 150000002632 lipids Chemical class 0.000 claims abstract description 27
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 235000000832 Ayote Nutrition 0.000 claims abstract description 17
- 235000009854 Cucurbita moschata Nutrition 0.000 claims abstract description 17
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 claims abstract description 17
- 235000015136 pumpkin Nutrition 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 6
- 208000008589 Obesity Diseases 0.000 claims abstract description 6
- 235000020824 obesity Nutrition 0.000 claims abstract description 6
- 206010002383 Angina Pectoris Diseases 0.000 claims abstract description 4
- 208000006011 Stroke Diseases 0.000 claims abstract description 4
- 201000001883 cholelithiasis Diseases 0.000 claims abstract description 4
- 208000037976 chronic inflammation Diseases 0.000 claims abstract description 4
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims abstract description 4
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 4
- 238000000605 extraction Methods 0.000 claims abstract description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 4
- 241000237858 Gastropoda Species 0.000 claims description 33
- 238000003756 stirring Methods 0.000 claims description 15
- 239000012299 nitrogen atmosphere Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 8
- 244000269722 Thea sinensis Species 0.000 claims description 7
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 6
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 6
- 230000006872 improvement Effects 0.000 claims description 6
- 240000001810 Angelica gigas Species 0.000 claims description 5
- 235000018865 Angelica gigas Nutrition 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 229920001817 Agar Polymers 0.000 claims description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 4
- 239000008272 agar Substances 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 208000014882 Carotid artery disease Diseases 0.000 claims description 3
- 230000002490 cerebral effect Effects 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 2
- 240000001980 Cucurbita pepo Species 0.000 claims 4
- 241000234280 Liliaceae Species 0.000 claims 2
- 241000125175 Angelica Species 0.000 claims 1
- 244000297179 Syringa vulgaris Species 0.000 claims 1
- 235000004338 Syringa vulgaris Nutrition 0.000 claims 1
- 238000004821 distillation Methods 0.000 claims 1
- 229940002508 ginger extract Drugs 0.000 claims 1
- 235000020708 ginger extract Nutrition 0.000 claims 1
- 239000002002 slurry Substances 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 56
- 238000004519 manufacturing process Methods 0.000 abstract description 30
- 238000002474 experimental method Methods 0.000 abstract description 24
- 230000007935 neutral effect Effects 0.000 abstract description 21
- 235000012000 cholesterol Nutrition 0.000 abstract description 17
- 239000008280 blood Substances 0.000 abstract description 15
- 210000004369 blood Anatomy 0.000 abstract description 15
- 240000004244 Cucurbita moschata Species 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 9
- 230000000845 anti-microbial effect Effects 0.000 abstract description 6
- 210000005084 renal tissue Anatomy 0.000 abstract description 6
- 201000010063 epididymitis Diseases 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 4
- 238000004220 aggregation Methods 0.000 abstract description 3
- 210000005228 liver tissue Anatomy 0.000 abstract description 3
- 244000241872 Lycium chinense Species 0.000 abstract description 2
- 235000015468 Lycium chinense Nutrition 0.000 abstract description 2
- 244000046146 Pueraria lobata Species 0.000 abstract description 2
- 235000010575 Pueraria lobata Nutrition 0.000 abstract description 2
- 239000011248 coating agent Substances 0.000 abstract description 2
- 238000000576 coating method Methods 0.000 abstract description 2
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 2
- 230000003013 cytotoxicity Effects 0.000 abstract description 2
- 210000000918 epididymis Anatomy 0.000 abstract description 2
- 241000931705 Cicada Species 0.000 abstract 3
- 230000001603 reducing effect Effects 0.000 abstract 2
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 abstract 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 abstract 1
- 244000090599 Plantago psyllium Species 0.000 abstract 1
- 235000010451 Plantago psyllium Nutrition 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 239000001180 angelica archangelica l. root extract Substances 0.000 abstract 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 abstract 1
- 208000006132 lipodystrophy Diseases 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 86
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 241000238631 Hexapoda Species 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000000378 dietary effect Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000001953 sensory effect Effects 0.000 description 6
- 240000002045 Guettarda speciosa Species 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 235000018823 dietary intake Nutrition 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 206010057190 Respiratory tract infections Diseases 0.000 description 3
- 241000194019 Streptococcus mutans Species 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 231100001083 no cytotoxicity Toxicity 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 235000011121 sodium hydroxide Nutrition 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000191070 Escherichia coli ATCC 8739 Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 240000004371 Panax ginseng Species 0.000 description 2
- 235000002789 Panax ginseng Nutrition 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 235000020710 ginseng extract Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000001596 intra-abdominal fat Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241001105098 Angelica keiskei Species 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 240000007324 Campanula punctata Species 0.000 description 1
- 235000016074 Campanula punctata Nutrition 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 241000410367 Clerodendrum thomsoniae Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241000219122 Cucurbita Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 240000006890 Erythroxylum coca Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- 208000006670 Multiple fractures Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- VUGRLRAUZWGZJP-UHFFFAOYSA-N Plantaginin Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 VUGRLRAUZWGZJP-UHFFFAOYSA-N 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 241000111850 Protaetia brevitarsis seulensis Species 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- RJWJHRPNHPHBRN-FKVJWERZSA-N aucubin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(CO)=C[C@@H](O)[C@@H]2C=CO1 RJWJHRPNHPHBRN-FKVJWERZSA-N 0.000 description 1
- UTDFQMAXCUGNJR-UHFFFAOYSA-N aucubin Natural products OCC1OC(Oc2ccoc2C3C(O)CCC3O)C(O)C(O)C1O UTDFQMAXCUGNJR-UHFFFAOYSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000020974 cholesterol intake Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 235000008957 cocaer Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000000850 deacetylating effect Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229910000078 germane Inorganic materials 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- VUGRLRAUZWGZJP-IAAKTDFRSA-N plantaginin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 VUGRLRAUZWGZJP-IAAKTDFRSA-N 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000001321 subclavian vein Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000013077 target material Substances 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/204—Animal extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/208—Fungi extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/51—Polysaccharide
- A23V2250/511—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/31—Mechanical treatment
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 굼벵이를 함유하는 다이어트 음료 및 그 제조방법에 관한 것으로, 보다 상세하게는 굼벵이를 주원료로 하여 늙은 호박 추출액, 구기자 추출액, 백복령 추출액, 차전자 추출액, 당귀 추출액 및 칡 추출액을 조성 비율에 따라 일정량씩 조합한 혼합 추출액을 키토산으로 표면코팅하여 집적화(self-aggregation)함으로써 굼벵이 특유의 역겨운 냄새를 없애고, 음용하기에 편리하며, 세포독성이 없으며, 생체 이용율이 향상되며, 항균활성이 우수할 뿐만 아니라, 혈중 콜레스테롤 및 중성지질 저하 효과가 우수한 다이어트 음료로 응용하는 기술에 관한 것이다.
The present invention relates to a diet drink containing slugs and a method of preparing the same, and more particularly, to a slimming diet containing slugs as a main ingredient, an old pumpkin extract, a Gugija extract, a Baekbokryeong extract, a tea extract, It is convenient to drink, to remove toxic odor peculiar to slugs by self-aggregation by surface coating with a mixed extract of chitosan combined with a certain amount, to have no cytotoxicity, to improve bioavailability, to have excellent antimicrobial activity The present invention also relates to a technology for application as a diet drink excellent in blood cholesterol and neutral lipid lowering effect.
비만은 그 자체로서도 위험하지만 동반되는 호흡장애, 심장질환, 동맥경화, 암 등의 합병증을 유발하여 현대인의 식이관리로서도 관리와 치료에 매우 중요하다. 현재 우리나라는 비만 치료제로서 식욕억제제의 일종인 시부트라민(sibutramine)과 지방흡수억제제인 올리스탄트(orlistant)를 사용하고 있는데 이는 혈압을 높이고, 심장박동을 빠르게 하여 관련 질환을 가지고 있는 사람에게는 주의를 요하는 부작용을 보이고 있다. 그러므로 천연물을 활용한 비만제어와 다이어트 관련 연구는 농산업의 발달과 함께 자원이 빈약한 우리나라의 전통적 한의학의 융합 기술이 접목되면 발전가능성은 물론 세계적 경쟁성도 가질 수 있는 분야로 필요성이 크다고 본다. Obesity is dangerous in itself, but it causes complications such as respiratory disorders, heart disease, arteriosclerosis and cancer, which are very important for management and treatment as modern dietary management. Currently, Korea is using sibutramine, an appetite suppressant, and orlistant, which is a fat absorption inhibitor, to raise blood pressure and accelerate heart rate, so it is important for people with related diseases. . Therefore, research on obesity control and diet using natural materials is needed for the development of agriculture industry and the possibility of global competitiveness as well as the possibility of development if the fusion technology of Korean traditional medicine is poor.
한편, 굼벵이(학명: Protaetia brevitarsis seulensis (Kolbe))는 흰점박이꽃무지 풍뎅이류에 속하는 애벌레(grub worm)를 지칭하며, 이것의 생약적 성질은 약간 차고 맛은 짜며 주로 악혈(惡血 나쁜 피), 어혈(血瘀 뭉친 피), 비기(痺氣 저리는 증세), 눈의 군살, 눈을 뜨고도 못보는 증세, 백막(白膜 눈동자에 하얀 것이 낌), 뼈가 부러지거나 부스러지거나 삔데, 쇠에 다쳐 속이 막힌 증세 등을 치료하며 젖을 잘나오게 한다고 우리나라 전통 의학서인 동의보감(東醫寶鑑)에 소개된 약재이며, 2014년 경기도 농업기술원에서 발표한 흰점박이꽃무지 유충(굼벵이)를 Rat을 상대로 3주간 개선 효과를 확인 발표한바 간기능을 실험한 결과 활성산소 제거 성분은 33.1%, 간 해독작용을 하는 총 글루타치온 함량은 51.2%, 간 손상 시 발생하는 효소 함량은 36.0~44.1% 낮아졌고, 중성지방 23.4%, 총콜레스테롤 18.4%, 동맥경화지수는 58.7%가 각각 낮아진 것으로 확인됐다.On the other hand, a slug (scientific name: Protaetia brevitarsis seulensis (Kolbe)) refers to a larva (grub worm) belonging to the white spotted bellflower, and its herbicidal properties are slightly colder, and taste is mainly weed, bad blood, bad blood, , White pimples (white in white pupil eyes), broken bones, broken or sprained, broken heart, and so on. It is a medicinal product introduced in Dongbok-bong (traditional medicine book), which is a traditional medicine of Korea. In 2014, it announced the improvement of the white spotted flower larva (slug) announced by Gyeonggi Province Agricultural Research Institute for three weeks against Rat As a result of liver function tests, 33.1% of active oxygen elimination component, 51.2% of total glutathione, and 36.0 ~ 44.1% of liver enzymes were decreased in liver damage, 23.4% of triglyceride, 18.4% of total cholesterol, , Arteriosclerosis index It was found to have 58.7% lower, respectively.
상기와 같이 굼벵이 관련 특허에는 꽃무지 유충(굼벵이) 유래 단백질원을 등록특허 제10-1359507호 식용 흰점박이꽃무지 유충 분말의 제조 방법, 등록특허 제10-1491771호 흰점박이꽃무지 현탁액의 제조방법 및 이를 포함하는 항비만 조성물, 등록특허 제10-1382400호 흰점박이꽃무지를 유효성분으로 포함하는 염증성질환의 예방 및 치료용조성물, 등록특허 제 10-1474900호 굼벵이를 주원료로 하는 스낵의 제조방법, 등록특허 제10-1616688호 굼벵이를 이용한 기능성식품 제조방법, 등록특허 제10-1349136호 곤충 글라이코사미노글리칸을 유효성분으로 포함하는 지방간 또는 고지혈증 예방 또는 치료용 조성물, 등록특허 제10-1622784 식용곤충을 이용한 다이어트 에너지바 및 그 제조방법, 등록특허 제 10-1493916호 곤충의 식용화 방법, 그 식용화된 곤충, 이러한 식용화된 곤충을 이용한 식품용 반죽의 제조방법 등 식품과 기능성으로서 연구되고 있다. As described above, the patent related to the slugs includes a protein source derived from a flower fly larva (Japanese Patent Registration No. 10-1359507), a method for producing white spotted spotted larvae for food, a registered patent No. 10-1491771, a method for producing a white spotted spotted flower suspension And an anti-obesity composition containing the same, a composition for preventing and treating an inflammatory disease comprising as an active ingredient a white spotted flower of the Japanese Patent Registration No. 10-1382400, a registered patent No. 10-1474900, a method for producing a snack using slugs as a main ingredient , Patent No. 10-1616688, Method for producing functional food using slugs, Registration No. 10-1349136, Composition for prevention or treatment of fatty liver or hyperlipidemia comprising insect glicosaminoglycan as an active ingredient, 1622784 Diet energy bar using edible insect and method of manufacturing thereof, Patent No. 10-1493916 Method of edifying insect, the edible insect, A is being studied as a functional food and the like method of manufacturing a food dough for using.
한편, 키토산(Chitosan)은 곤충 및 갑각류의 껍질인 새우, 게와 버섯 등에 키틴질로 존재하고 있으며 화학명이 Poly (1→4) 2-amino-2-deoxy-β-D-Glucan이다. 키틴질은 유효 이용율이 적어, 주로 수용화하거나, 발효시키거나, 다른 유도체로 제조하여 다양한 범위에 활용하고 있다. 키토산의 특성은 항산화력과 항균력, 콜레스테롤 조절, 지방흡착, 전달 기능이 이미 알려진 생체재료로서 제약과 식품, 화장품분야, 생활용품분야에서 우수성이 알려져 있어 천연 생체재로서 다양하게 이용되고 있다.On the other hand, chitosan is present as chitin in shrimp, crab and mushroom which are the bark of insects and crustaceans, and the chemical name is Poly (1 → 4) 2-amino-2-deoxy-β-D-Glucan. Chitin has a low effective utilization rate and is mainly used for various purposes such as water-soluble, fermentable, or other derivatives. The properties of chitosan are variously used as natural biomaterials because they are well known in the fields of pharmaceuticals, foods, cosmetics, and household goods, and have known antioxidant ability, antimicrobial activity, cholesterol control, lipid adsorption and transfer function.
약재 발효키토산 관련 특허에는 등록특허 제10-1564668호 본초 발효 키토산의 제조방법과 그 이용, 등록특허 제10-1659927호 본초의 약효 증대방법, 면역증강용 발효 키토산의 제조방법, 및 그 이용 및 등록특허 제10-0735675호 저분자량 및 친수성을 높여 콜라겐의 유효 이용율을 향상시키기 위한 제조방법이 있다.The patent related to the fermented chitosan for use in medicines is described in Patent No. 10-1564668, and a method for preparing the fermented chitosan for immune enhancement, and its use and registration Patent No. 10-0735675 There is a manufacturing method for improving the effective utilization ratio of collagen by increasing the low molecular weight and hydrophilicity.
최근에는 웰빙, 건강, 다이어트, 전통 등을 결합한 다양한 건강 음료가 인기를 얻으며 음료 및 외식업계의 관련 제품 출시경쟁이 치열하다. 이에 따라 굼벵이 또는 키토산을 이용한 건강 제품이 다수 개발되어 출시되고 있지만, 굼벵이 특유의 역한 냄새가 제거되지 못하고 관능 기호도가 낮아 소비자들의 욕구를 만족시키지 못한 문제가 있으며, 생체 이용율, 항균 활성 및 내장지방과 콜레스테롤 저하 효과는 미비한 있는 실정이다. In recent years, a variety of health drinks that combine wellness, health, diet, and tradition have gained popularity, and competition to launch related products in the beverage and restaurant industry is fierce. Accordingly, many health products using slugs or chitosan have been developed and marketed. However, there is a problem that the unique smell of slugs can not be removed and the sensory preference is low and the consumer's desire is not satisfied. The bioavailability, antibacterial activity, The effect of cholesterol lowering is insufficient.
따라서, 굼벵이 특유의 냄새가 제거되고 관능 기호도가 우수하여 소비자의 욕구를 만족시킬 수 있으며, 생체 이용율, 항균 활성 및 내장지방과 콜레스테롤 저하 효과가 우수한 굼벵이 함유 다이어트 음료가 요구되고 있다.
Therefore, there is a demand for a slug-containing diet drink excellent in bioavailability, antimicrobial activity, visceral fat and cholesterol-lowering effect, which can satisfy consumer's desire because of its unique smell removed from the slugs and excellent in sensory preference.
본 발명은 상기와 같은 문제점을 고려하여 안출된 것으로, 본 발명의 목적은 굼벵이를 주원료로 하여, 굼벵이 특유의 역겨운 냄새를 없애고, 음용하기에 편리하며, 세포독성이 없으며, 생체 이용율이 향상되며, 항균활성이 우수할 뿐만 아니라, 혈중 콜레스테롤 및 중성지질 저하 효과가 우수한 다이어트 음료를 제공하고자 하는 것이다.
DISCLOSURE OF THE INVENTION The present invention has been made in view of the above problems, and it is an object of the present invention to provide a method for removing slimy odor, which is convenient for drinking, cytotoxicity, bioavailability, Which has excellent antimicrobial activity and is excellent in blood cholesterol and neutral lipid lowering effect.
상기한 바와 같은 목적을 달성하기 위한 본 발명은, 굼벵이 추출액 10 내지 50 중량%, 늙은 호박 추출액 5 내지 30 중량%, 구기자 추출액 3 내지 20 중량%, 백복령 추출액 5 내지 20 중량%, 차전자 추출액 5 내지 30 중량%, 칡 추출액 3 내지 10 중량% 및 당귀 추출액 5 내지 20 중량%를 함유하는 혼합 추출액; 및 상기 혼합 추출액 전체 중량에 대해 0.5 내지 10 중량%의 키토산;을 포함하는 것을 특징으로 하는 굼벵이를 함유하는 다이어트 음료를 제공한다.In order to achieve the above-mentioned object, the present invention provides a method for producing a safflower extract, comprising: 10 to 50% by weight of a slug extract, 5 to 30% by weight of an old pumpkin extract, 3 to 20% By weight to 30% by weight of the extract, 3 to 10% by weight of the extract and 5 to 20% by weight of the extract of Angelica gigas Nakai; And 0.5 to 10% by weight of chitosan based on the total weight of the mixed extract.
상기 굼벵이를 함유하는 다이어트 음료는 고콜레스테롤혈증, 고지혈증 또는 이들의 합병증으로서 관상 동맥 질환, 협심증, 경동맥 질환, 뇌졸증, 뇌동맥경화증, 콜레스테롤 담석, 제Ⅱ형 당뇨병, 지질 이상증, 비만 및 만성 염증성 장애로 이루어진 군으로부터 선택되는 질환의 개선 또는 예방이 가능할 수 있다.The diet drink containing the slugs may be selected from the group consisting of hypercholesterolemia, hyperlipidemia or a complication thereof consisting of coronary artery disease, angina pectoris, carotid artery disease, stroke, cerebral arterial sclerosis, cholesterol gallstone, type II diabetes, lipid disorders, obesity and chronic inflammatory disorders Improvement or prevention of a disease selected from the group may be possible.
또한, 본 발명은 (a) 굼벵이 추출액 10 내지 50 중량%, 늙은 호박 추출액 5 내지 30 중량%, 구기자 추출액 3 내지 20 중량%, 백복령 추출액 5 내지 20 중량%, 차전자 추출액 5 내지 30 중량%, 칡 추출액 3 내지 10 중량% 및 당귀 추출액 5 내지 20 중량%를 혼합하여 혼합 추출액을 수득하는 단계; 및 (b) 상기 혼합 추출액 전체 중량에 대해 0.5 내지 10 중량%의 키토산을 혼합하여 혼합액을 수득하는 단계;를 포함하는 굼벵이를 함유하는 다이어트 음료의 제조방법을 제공한다.The present invention also relates to a method for producing the extract of the present invention which comprises (a) 10 to 50% by weight of a slug extract, 5 to 30% by weight of an old pumpkin extract, 3 to 20% by weight of a gugija extract, 5 to 20% 3 to 10% by weight of the extract and 5 to 20% by weight of the extract of Angelica gigantosa L. extract to obtain a mixed extract; And (b) mixing 0.5 to 10% by weight of chitosan with respect to the total weight of the mixed extract to obtain a mixed solution.
상기 굼벵이 추출액은, 고압멸균 및 동결건조된 굼벵이에 물을 6 내지 15 배 중량으로 혼합한 혼합물을 80 내지 150 ℃에서 8 내지 20 시간 동안 증류 추출하여 제조될 수 있다.The slug extract can be prepared by distilling a mixture of 6 to 15 times by weight of water with high-pressure sterilized and freeze-dried slugs at 80 to 150 ° C for 8 to 20 hours.
상기 늙은 호박 추출액, 구기자 추출액, 백복령 추출액, 차전자 추출액, 칡 추출액 및 당귀 추출액 각각은, 늙은 호박, 구기자, 백복령, 차전자, 칡 또는 당귀에 물을 25 내지 50 배 중량으로 혼합한 혼합물을 80 내지 150 ℃에서 8 내지 20 시간 동안 증류 추출하여 제조될 수 있다.Each of the old pumpkin extract, Gugija extract, Baekbokryei extract, tea extract, chrysanthemum extract and Angelica gigantum extract was mixed with 25 to 50 times by weight of water to old pumpkin, gugija, To < RTI ID = 0.0 > 150 C < / RTI > for 8 to 20 hours.
상기 (b) 단계는 질소 분위기 및 60 내지 120 ℃ 조건에서 3000 내지 5000 RPM으로 교반하여 수행될 수 있다.The step (b) may be performed in a nitrogen atmosphere and at a temperature of 60 to 120 ° C with stirring at 3000 to 5000 RPM.
상기 제조방법은 (c) 상기 혼합액 및 한천을 혼합하여 겔상화 한 후 살균하는 단계;를 더욱 포함할 수 있다.
The manufacturing method may further include (c) mixing the mixture and agar to gel, and sterilizing the mixture.
본 발명에 따르면, 굼벵이를 주원료로 하여 늙은 호박 추출액, 구기자 추출액, 백복령 추출액, 차전자 추출액, 당귀 추출액 및 칡 추출액을 조성 비율에 따라 일정량씩 조합한 혼합 추출액을 키토산으로 표면코팅하여 집적화(self-aggregation)함으로써 굼벵이 특유의 역겨운 냄새를 없애고, 음용하기에 편리하며, 세포독성이 없으며, 생체 이용율이 향상되며, 항균활성이 우수할 뿐만 아니라, 혈중 콜레스테롤 및 중성지질 저하 효과가 우수한 다이어트 음료를 제공할 수 있다.
According to the present invention, a mixed extract prepared by combining old pumpkin extract, Gugija extract, Baekbok-ri extract, Cha-eu extract, Angelica keiskei extract, aggregation to provide a diet drink which is excellent in eliminating the unpleasant smell unique to the slugs, is convenient for drinking, has no cytotoxicity, has improved bioavailability, is excellent in antimicrobial activity, and has a blood cholesterol and neutral lipid lowering effect .
도 1은 본 발명의 실시예 1로부터 제조된 굼벵이를 함유하는 다이어트 음료의 (a) 투과전자현미경(TEM) 이미지 및 (b) 직접화(self-aggregation)된 입자 모식도이다.BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a transmission electron microscope (TEM) image and (b) a self-aggregated particle schematic diagram of (a) a slime-containing diet drink prepared from Example 1 of the present invention.
이하에서, 본 발명의 여러 측면 및 다양한 구현예에 대해 더욱 구체적으로 설명한다.In the following, various aspects and various embodiments of the present invention will be described in more detail.
본 발명은 굼벵이 추출액 10 내지 50 중량%, 늙은 호박 추출액 5 내지 30 중량%, 구기자 추출액 3 내지 20 중량%, 백복령 추출액 5 내지 20 중량%, 차전자 추출액 5 내지 30 중량%, 칡 추출액 3 내지 10 중량% 및 당귀 추출액 5 내지 20 중량%를 함유하는 혼합 추출액; 및 상기 혼합 추출액 전체 중량에 대해 0.5 내지 10 중량%의 키토산;을 포함하는 것을 특징으로 하는 굼벵이를 함유하는 다이어트 음료에 관한 것이다.The present invention relates to a method for producing a roasted poultice, which comprises 10 to 50% by weight of a slug extract, 5 to 30% by weight of an old pumpkin extract, 3 to 20% by weight of a Gujija extract, 5 to 20% And 5 to 20% by weight of Angelica gigas Nakai extract; And 0.5 to 10% by weight of chitosan based on the total weight of the mixed extract.
늙은 호박(南瓜, Cucurbita spp.)은 칼로리가 적고 몸속 노폐물을 배출하며 이뇨작용을 촉진해 다이어트와 피부미용에 좋고, 산후 및 수술 후 부기를 빼는데도 많이 애용된다. Old pumpkin (Cucurbita spp.) Is low in calories, emits waste in the body, promotes diuretic action, is good for diet and skin beauty, and is widely used to remove postpartum and post-operative swelling.
구기자(枸杞子, Lycium chinense Miller)는 수렴성으로 예로부터 성기능개선에 많이 사용되어 오고 있으며 약성은 달고(甘) 차다(寒). 허리와 무릎에 힘이 없으며 음혈이 허약해져 얼굴이 누렇고 머리털이 희어지며 잠을 못 이룰 때나 소갈증에 효과가 있고 약리작용으로 비특이성면역증강 작용, 조혈작용, 콜레스테롤강하작용, 항지방간작용, 혈압강하, 혈당강하 등이 보고되었다. 무더위에 땀을 많이 흘려 지치고 피로한 몸의 기운을 보충하는데 좋으며 베타인(Betaine) 성분이 간에 지방축적을 억제하고, 손상된 간을 회복시키며 베타카로틴과 비타민C도 많아 피부미용 등에도 좋은 소재이다. Lycium chinense Miller has been widely used for sexual function improvement since its convergence, and its weakness is sweet (cold). There is no strength in the back and knee, weakness in the blood, weakness in the face, whitish hair, effective in sleeping when not sleeping, pharmacological action, non-specific immune enhancement, hematopoiesis, cholesterol lowering, anti- Blood glucose levels were reported. It is good for supplementing the energy of tiredness and fatigued body. It is good for Betaine to inhibit liver fat accumulation, to restore damaged liver, and also to have a lot of beta carotene and vitamin C.
백복령(白茯笭, Poria cocas Wolf)은 맛은 달고 담담하며 성질은 어느 한 쪽으로 치우지지 않고 평(平)하며, 심장, 비장 및 폐에 작용한다. 주로 비장 기능을 튼튼하게 하고 이뇨작용을 촉진하는 작용이 있어 비장의 기능이 허약하고 인체의 수액대사가 원활하지 못하여 발생하는 여러 증상에 모두 응용되며 특별한 부작용은 없는 소재로서 다공균과(구멍쟁이버섯과)에 속한 진균인 복령의 균핵을 말한다. 복령은 특징과 가공방법에 따라 적복령(赤茯笭), 복신(茯神), 복령피(茯笭皮) 등으로 구분되며 각각의 약효는 조금씩 다르다. 7 월부터 다음 해 3 월 사이에 소나무 숲에서 채취하여 약재로 이용한다. Poria cocas wolf is taste and sweet, its quality is not cleared to one side, it acts on heart, spleen and lungs. It is mainly applied to various symptoms caused by weak spleen function and smooth metabolism of the human body due to its action of strengthening spleen function and promoting diuretic action, and has no particular adverse effect. And fungi belonging to the fungus of the sclerotium refers to. Depending on the characteristics and processing methods, the gyeongryeong is divided into red ginseng (red ginseng), ginseng (ginseng), and bokryeoppy (茯 笭 skin). From July to March of next year, it is collected from pine forests and used as medicinal material.
차전자(車前子, Plantaginis Semen)는 질경이 씨앗으로 열을 제거하며 담(痰)을 없애며 시력을 좋게 하는 효능을 가지고 있다. 맛은 달고(甘) 성질은 차며(寒) 이수통림, 삼습지사, 청간명목에 잎과 씨를 약재로 사용하며 잎을 차전(車前), 씨를 차전자(車前子)라고 한다. 잎과 씨는 모두 이뇨, 해열, 거담, 진해의 효능을 가지고 있다. 씨는 방광염, 요도염, 임질, 설사, 간염, 고혈압 등에 효과를 보이며, 잎은 소변이 잘 나오지 않는 증세를 비롯하여 감기, 기침, 기관지염, 인후염, 황달, 간염, 혈뇨 등의 치료에 쓰인다. 잎에는 플란타기닌(Plantaginin)과 아우쿠빈(Aucubin)이 함유되어 있으며 씨는 물을 흡수하여 팽윤되는 섬유질이 많이 함유되어 배변활동에도 도움이 된다. The tea plant (Plantaginis Semen) has the effect of removing heat with plantain seeds and eliminating the phlegm and improving the sight. The taste is sweet and the quality is cold. Ishim Jung Lim, Samgwaji Co., uses the leaves and seeds as medicinal materials in the name of blue, and the leaves are called "car" and "tea". Both leaves and seeds have the efficacy of diuretic, fever, germane and Jinhae. Seeds are effective for cystitis, urethritis, gonorrhea, diarrhea, hepatitis and hypertension. Leaves are used for the treatment of colds, coughs, bronchitis, sore throat, jaundice, hepatitis and hematuria as well as symptoms of poor urination. The leaves contain plantaginin and aucubin. Seeds absorb the water and contain a lot of swelling fiber, which helps the bowel movement.
칡(葛根, Pueraria lobata (Willd.) ohwi)은 주로 흙속의 진주라 하는 뿌리를 이른 봄·늦가을에 채취하여 잘라서 햇볕에 말려 사용한다. 성미귀경은 감(甘), 신(辛), 량(凉). 무독(無毒)하고, 비(脾), 위(胃), 폐(肺), 방광(膀胱)에 귀경한다. 외감으로 인한 발열 두통, 무한, 항배강통 등의 증후를 치료한다. 땀을 나게 하여 술독으로 인한 번갈을 없애주며, 음식 맛을 나게 하고 소화를 잘 되게 하며 가슴의 열을 없애 준다. 고혈압, 뇌질환, 이명, 사지가 저리는 증상 등을 개선하며 석류의 600 배 넘는 식물성 에스트로겐 성분 다량 함유로 여성갱년기 건강에 효과적이다라는 보고도 있다. 칡 (Pueraria lobata (Willd.) Ohwi) is mainly extracted from the soil in early spring and late autumn, cut into rhizomes, and dried in the sun. Sungwi is the sweetness, the god, the quantity. It is nontoxic, and goes to the spleen, the stomach, the lungs and the bladder. It treats the symptoms such as fever headache, infinite, and anti-sickness due to the external appearance. It sweats, eliminates the burning caused by the digestion, makes the food taste, digest well, and eliminates the heat of the chest. Hypertension, brain disease, tinnitus, lower limb symptoms and improve the pomegranate pomegranate more than 600 times the amount of vegetable estrogen is a large amount of health is also effective in women's menopausal health is also reported.
당귀(當歸, Angelica gigas Nakai)는 우리나라에서 참당귀(Angelica gigas Nakai) 뿌리를 사용한다. 늦가을에 캐어 노두(蘆頭)와 수근(鬚根)은 제거하고 얇게 썰어서 술로 반죽하거나 혹은 술로 볶아서 사용한다. 맛은 달고 매우며 성질은 따뜻하다. 당귀에는 정유, 저당, 비타민B12 등이 포함되어 있다. 혈을 보하고 지통의 효능도 매우 우수하여 월경부조, 폐경, 통경 등 여성에게 매우 좋은 약재이다. 혈허로 인한 장조변비, 즉 대변이 딱딱하고 건조한 변비, 노인성 변비에도 좋다. 당귀를 삶은 물로 세안을 하면 피부가 윤택해지고 여드름에도 효과가 있다. Angelica gigas Nakai uses Angelica gigas Nakai roots in Korea. In late autumn, remove the head (蘆 head) and the root (鬚 根) and cut it into thin slices and knead it with alcohol or roast it with alcohol. The taste is sweet and very warm and the quality is warm. Angelica contains essential oil, mortar and vitamin B12. It is very good medicine for women such as menstruation relief, menopause, and menstrual flow, because it has excellent blood circulation and efficacy. Constipation due to blood vessels, such as constipation, stiff and dry constipation, geriatric constipation is good. If you wash your face with water, you can make your skin moisturized and acne effective.
본 발명에 따른 굼벵이를 함유하는 다이어트 음료는 키토산을 이용하여 상술한 천연 생약식품의 유효성분이 효율적으로 집적되도록 하여, 음용하기에 편리할 뿐만 아니라, 굼벵이의 역겨운 냄새를 제거하고, 항균활성 및 생체 이용율을 증대시킨 효과가 있다. The diet drink containing the slugs according to the present invention is advantageous in that the active ingredients of the natural herbal medicine described above can be efficiently accumulated by using chitosan so that it is not only convenient for drinking but also eliminates the unpleasant smell of slugs and has antibacterial activity and bioavailability .
도 1의 본 발명의 실시예 1로부터 제조된 굼벵이를 함유하는 다이어트 음료의 (a) 투과전자현미경(TEM) 이미지 및 (b) 직접화(self-aggregation)된 입자 모식도를 통하여 이를 설명할 수 있다.(A) transmission electron microscope (TEM) images and (b) self-aggregated particle flow diagrams of the slimy diet drink prepared from Example 1 of the present invention in Fig. 1 .
도 1(a)를 참조하면, 키토산의 표면처리에 의해 혼합 추출액이 집적화(self-aggregation)되어 마이셀(micelle) 형태를 나타낼 수 있음을 확인할 수 있다. Referring to FIG. 1 (a), it can be confirmed that the mixed extract is self-aggregated by the surface treatment of chitosan to exhibit a micelle shape.
도 1(b)에는 도 1(a)의 마이셀 입자 하나를 구체적으로 형상화하여 나타내었는데, 4 개의 초록색 입자는 본 발명에 따른 혼합 추출액을 나타내며, 4 개의 초록색 입자를 감싸고 있는 황토색의 형상은 키토산을 나타낸다. 이를 통하여, 키토산에 의하여 혼합 추출액이 표면코팅되어 있음을 이해할 수 있다. 즉, 혼합 추출액의 추출성분, 약성성분 또는 유효성분이 키토산에 의하여 집적화(self-aggregation) 되었음을 의미할 수 있다.1 (b) shows a micellar particle of FIG. 1 (a) in detail, wherein the four green particles represent the mixed extract according to the present invention, and the ocher color surrounding the four green particles is chitosan . As a result, it can be understood that the mixed extract is coated on the surface by chitosan. That is, it may mean that the extracted component, the weak component or the active ingredient of the mixed extract is self-aggregated by chitosan.
상기 굼벵이를 함유하는 다이어트 음료는 고콜레스테롤혈증, 고지혈증 또는 이들의 합병증으로서 관상 동맥 질환, 협심증, 경동맥 질환, 뇌졸증, 뇌동맥경화증, 콜레스테롤 담석, 제Ⅱ형 당뇨병, 지질 이상증, 비만 및 만성 염증성 장애로 이루어진 군으로부터 선택되는 질환의 개선 또는 예방이 가능할 수 있다. 상기 나열된 질환에만 국한되는 것은 아니다.The diet drink containing the slugs may be selected from the group consisting of hypercholesterolemia, hyperlipidemia or a complication thereof consisting of coronary artery disease, angina pectoris, carotid artery disease, stroke, cerebral arterial sclerosis, cholesterol gallstone, type II diabetes, lipid disorders, obesity and chronic inflammatory disorders Improvement or prevention of a disease selected from the group may be possible. It is not limited to the diseases listed above.
콜렉스테롤을 과다하게 섭취하고, 운동 등으로 과다 섭취한 콜레스테롤을 소비하지 않는 경우, 콜레스테롤 과다 섭취에 의한 질환이 발생될 수 있다. 상기 과다 섭취로 인한 질환이란 콜레스테롤 조절 기능에 이상이 생겨 체내 또는 혈관에 콜레스테롤이 적정 수준 이상으로 축적되는 질환인 고콜레스테롤증 또는 이로 인해 유발되는 질병을 의미하며, 콜레스테롤 대사 이상 관련 질환이라고도 한다.If you take too much cholesterol and do not consume excess cholesterol from exercise, you may develop a disease caused by excessive cholesterol intake. The disorder caused by the excessive intake refers to a hypercholesterolemia or a disease caused by the abnormality in cholesterol control function and accumulating cholesterol in the body or blood vessels at an appropriate level or higher, and it is also referred to as a cholesterol metabolism disorder-related disorder.
또한, 본 발명은 (a) 굼벵이 추출액 10 내지 50 중량%, 늙은 호박 추출액 5 내지 30 중량%, 구기자 추출액 3 내지 20 중량%, 백복령 추출액 5 내지 20 중량%, 차전자 추출액 5 내지 30 중량%, 칡 추출액 3 내지 10 중량% 및 당귀 추출액 5 내지 20 중량%를 혼합하여 혼합 추출액을 수득하는 단계; 및 (b) 상기 혼합 추출액 전체 중량에 대해 0.5 내지 10 중량%의 키토산을 혼합하여 혼합액을 수득하는 단계;를 포함하는 굼벵이를 함유하는 다이어트 음료의 제조방법을 제공한다.The present invention also relates to a method for producing the extract of the present invention which comprises (a) 10 to 50% by weight of a slug extract, 5 to 30% by weight of an old pumpkin extract, 3 to 20% by weight of a gugija extract, 5 to 20% 3 to 10% by weight of the extract and 5 to 20% by weight of the extract of Angelica gigantosa L. extract to obtain a mixed extract; And (b) mixing 0.5 to 10% by weight of chitosan with respect to the total weight of the mixed extract to obtain a mixed solution.
상기 굼벵이 추출액은, 고압멸균 및 동결건조된 굼벵이에 물을 6 내지 15 배 중량으로 혼합한 혼합물을 80 내지 150 ℃에서 8 내지 20 시간 동안 증류 추출하여 제조될 수 있다. The slug extract can be prepared by distilling a mixture of 6 to 15 times by weight of water with high-pressure sterilized and freeze-dried slugs at 80 to 150 ° C for 8 to 20 hours.
구체적인 예로, 먼저, 2 내지 5일 동안 절식한 굼벵이를 90 내지 160 ℃, 바람직하게는 110 내지 130 ℃, 0.5 내지 2.0 kgf/cm3, 바람직하게는 0.8 내지 1.5 kgf/cm3 및 포화수증기 조건으로 5 내지 25 분, 바람직하게는 10 내지 15 분 동안 고압멸균 하는 단계;를 통하여 효소와 조직 단백질의 비가역적 응고와 변성을 막을 수 있다. As a specific example, the slugs fasted for 2 to 5 days are heated at 90 to 160 ° C, preferably 110 to 130 ° C, 0.5 to 2.0 kgf / cm 3, preferably 0.8 to 1.5 kgf / cm 3 and saturated steam conditions High pressure sterilization for 5 to 25 minutes, preferably 10 to 15 minutes, can prevent irreversible coagulation and denaturation of enzyme and tissue proteins.
상기 고압멸균된 굼벵이를 -40 내지 -100 ℃, 바람직하게는 -60 내지 -80 ℃에서 8 내지 30 시간, 바람직하게는 12 내지 24 시간 동안 냉동시킨 후 20 내지 55 시간, 바람직하게는 24 내지 48 시간 동안 동결건조하는 단계; 및 The autoclaved slugs are frozen at -40 to -100 ° C, preferably -60 to -80 ° C for 8 to 30 hours, preferably 12 to 24 hours, and then frozen for 20 to 55 hours, preferably 24 to 48 hours Lyophilizing for a period of time; And
상기 동결건조된 굼벵이에 물을 8 내지 12 배 중량, 바람직하게는 9 내지 11 배 중량으로 혼합한 혼합물을 110 내지 120 ℃, 바람직하게는 113 내지 117 ℃에서 10 내지 14 시간, 바람직하게는 11 내지 13 시간 동안 증류 추출하는 단계;를 통하여 굼벵이 추출액을 제조할 수 있다.The lyophilized slugs are mixed with water in an amount of 8 to 12 times by weight, preferably 9 to 11 times by weight, at 110 to 120 ° C, preferably at 113 to 117 ° C for 10 to 14 hours, Followed by distillative extraction for 13 hours to prepare a slug extract.
이러한 굼벵이 추출액 제조 단계를 통하여, 굼벵이의 식품화에 있어서 혐오성 및 풍미 등의 문제를 개선시킬 수 있다.Through such a step of producing the slug extract, it is possible to improve problems such as aversion and flavor in the food of slugs.
상기 늙은 호박 추출액, 구기자 추출액, 백복령 추출액, 차전자 추출액, 칡 추출액 및 당귀 추출액 각각은, 늙은 호박, 구기자, 백복령, 차전자, 칡 또는 당귀에 물을 25 내지 50 배 중량, 바람직하게는 30 내지 40 배 중량으로 혼합한 혼합물을 80 내지 150 ℃, 바람직하게는 110 내지 120 ℃, 더욱 바람직하게는 113 내지 117 ℃에서 8 내지 20 시간, 바람직하게는 10 내지 14 시간, 더욱 바람직하게는 11 내지 13 시간 동안 증류 추출하여 제조될 수 있다.Each of the old pumpkin extract, Gugija extract, Baekbokryeong extract, tea extract, ginseng extract and ginseng extract is mixed with 25 to 50 times by weight water, preferably 30 to 50 times by weight, 40 times the weight of the mixture is heated at 80 to 150 DEG C, preferably 110 to 120 DEG C, more preferably 113 to 117 DEG C for 8 to 20 hours, preferably 10 to 14 hours, more preferably 11 to 13 hours For a period of time.
상기 키토산의 수평균 분자량은 10 만 내지 25 만, 바람직하게는 13 내지 18 만, 더욱 바람직하게는 14 만 내지 16 만일 수 있으며, 키토산의 혼합량은 바람직하게는 1 내지 3%일 수 있다.The number average molecular weight of the chitosan may be 100,000 to 250,000, preferably 13 to 180,000, more preferably 140,000 to 16, and the amount of chitosan to be mixed may preferably be 1 to 3%.
상기 키토산 제조의 구체적인 예로, 곤충의 갑각 및 2 내지 8 중량%의 염산 수용액의 혼합물을 상온에서 20 내지 25 시간, 바람직하게는 22 내지 23 시간 동안 교반하여 무기질을 제거하는 단계; 상기 무기질이 제거된 혼합물 및 1 내지 6 중량% 가성소다 수용액의 혼합물을 80 내지 100 ℃, 바람직하게는 85 내지 90 ℃에서 3 내지 8 시간, 바람직하게는 5 내지 6 시간 동안 교반 및 가열하여 유기질을 제거하는 단계; 상기 유기질이 제거된 혼합물 및 40 내지 50 중량% 가성소다 수용액의 혼합물을 가열하여 탈아세틸화시키는 단계; 및 상기 탈아세틸화된 혼합물을 여과하여 수득한 고형상을 진공건조하는 단계;를 통하여 수평균 분자량 10 만 내지 25 만의 키토산을 제조할 수 있다.As a specific example of the production of the chitosan, stirring the mixture of a crust of an insect and an aqueous hydrochloric acid solution of 2 to 8% by weight at room temperature for 20 to 25 hours, preferably 22 to 23 hours, The mixture of the inorganic depleted mixture and the 1-6 wt% caustic soda aqueous solution is stirred and heated at 80 to 100 캜, preferably 85 to 90 캜, for 3 to 8 hours, preferably 5 to 6 hours, Removing; Deacetylating a mixture of the organic depleted mixture and a 40-50 wt% aqueous sodium hydroxide solution by heating; And chitosan having a number average molecular weight of 100,000 to 250,000 can be prepared through vacuum drying the solid shape obtained by filtering the deacetylated mixture.
상기 (b) 단계는 질소 분위기 및 60 내지 120 ℃, 바람직하게는 80 내지 100 ℃ 조건에서 3000 내지 5000 RPM, 바람직하게는 3500 내지 4000 RPM으로 교반하여 수행될 수 있으며, 교반시간은 제한되진 않지만 1 내지 30 분, 바람직하게는 10 내지 20 분 동안 수행될 수 있다.The step (b) may be carried out in a nitrogen atmosphere at a temperature of 60 to 120 ° C, preferably 80 to 100 ° C, at a temperature of 3000 to 5000 RPM, preferably 3500 to 4000 RPM, To 30 minutes, preferably 10 to 20 minutes.
상기 (b) 단계의 수행 조건에서, 온도 범위 및 교반속도 범위가 상기 수치범위를 벗어나거나, 질소 분위기가 아닐 경우에는 제조되는 다이어트 음료의 생체 이용율, 항균활성, 체중감량 효과, 혈중 콜레스테롤 및 중성지질 감소 효과가 현저히 저하됨을 확인하였다.If the temperature range and the stirring speed range are out of the above-mentioned numerical range or not in the nitrogen atmosphere, the bioavailability, antimicrobial activity, weight loss effect, blood cholesterol and neutral lipid And the reduction effect was remarkably decreased.
상기 제조방법은 (c) 상기 혼합액 및 한천을 혼합하여 겔상화 한 후 살균하는 단계;를 더욱 포함할 수 있다. The manufacturing method may further include (c) mixing the mixture and agar to gel, and sterilizing the mixture.
구체적인 예로, 혼합액 대비 0.5 내지 5 중량%, 바람직하게는 1 내지 3 중량%의 한천을 혼합할 수 있으며, 살균은 90 내지 100 ℃에서 3 내지 10 분 동안 수행될 수 있다.As a specific example, 0.5 to 5% by weight, preferably 1 to 3% by weight of the agar may be mixed with the mixed solution, and sterilization may be performed at 90 to 100 ° C for 3 to 10 minutes.
이하에서는 본 발명에 따른 제조예 및 실시예를 첨부된 도면과 함께 구체적으로 설명한다.
Hereinafter, production examples and embodiments according to the present invention will be described in detail with reference to the accompanying drawings.
제조예 1: 굼벵이 추출액의 제조Preparation Example 1: Preparation of slug extract
굼벵이는 3 일간 절식시키고 잘 세척한 후 동결건조하여 사용하였다. 먼저 3 령 이후의 3 g 이상의 굼벵이로 선별하여 포화수증기하의 고압멸균기에서 120 ℃ 및 1.0 kgf/cm3의 조건으로 13 분 동안 고압멸균 후 -70 ℃의 냉동고에서 20 시간 냉동시키고, 동결건조기에서 30 시간 건조하였다. 이후, 건조된 굼벵이 1,000 g을 정제수 10,000 mL에 넣고 115 ℃에서 12 시간에 걸쳐 증류 추출하여 굼벵이 추출액을 제조하였다.
The slugs were fasted for 3 days, washed well and lyophilized. First to third instar screening of at least 3 g of the slugs after 20 hours and frozen at -70 ℃ freezer then autoclaved for 13 minutes, and the saturated water vapor in the autoclave 120 ℃ and 1.0 kgf / cm 3 under a condition, in the freeze-dryer 30 Lt; / RTI > Then 1,000 g of dried slugs were added to 10,000 mL of purified water and distilled at 115 ° C for 12 hours to prepare a slug extract.
제조예 2: 혼합 추출액의 제조Production Example 2: Preparation of mixed extract
잘 건조된 늙은 호박의 추출액은 300 g의 늙은 호박을 정제수 10,000 ml에 넣고 115 ℃에서 12 시간에 걸쳐 증류 추출하여 제조하였다.A well-dried old pumpkin extract was prepared by adding 300 g of old pumpkin to 10,000 ml of purified water and distilling the mixture at 115 ° C for 12 hours.
상기와 동일한 방식으로 구기자, 백복령, 차전자, 칡 및 당귀를 각각 추출하여 각각의 추출액을 제조하였고, 상기 제조예 1로부터 제조된 굼벵이 추출액 30 중량%, 늙은 호박 추출액 10 중량%, 구기자 추출액 8 중량%, 백복령 추출액 13 중량%, 차전자 추출액 15 중량%, 당귀 추출액 15 중량% 및 칡 추출액 9 중량%을 30 분 동안 혼합하여 혼합 추출액을 제조하였다.
Each of the extracts was prepared by extracting Gugija, Baekbokryeong, Chaejeon, Chung, and Angelicae in the same manner as above. The extracts of 30% by weight of the slug extract prepared in Preparation Example 1, 10% by weight of the old pumpkin extract, , 15% by weight of Baekbokryoung extract, 15% by weight of tea extract, 15% by weight of Angelica gigantosa extract, and 9% by weight of Lilium extract were mixed for 30 minutes to prepare a mixed extract.
제조예 3: 키토산의 제조Production Example 3: Preparation of chitosan
수거한 곤충 갑각을 5% 염산용액에서 20 시간 상온에서 교반하며 무기질을 제거 하였으며, 가성소다 3% 용액하에서 5 시간 80 ℃에서 교반 가열하여 유기질을 제거하여 키틴질을 얻어내었으며, 이것을 45% 가성소다 용액하에 가열하면서 탈아세틸화 반응을 하여 여과로 걸러진 고형상을 진공건조하여, 수평균 분자량 15 만의 키토산을 제조하였다.
The collected insect carcass was stirred in 5% hydrochloric acid solution for 20 hours at room temperature to remove the minerals. The organic matter was removed by heating at 80 ° C for 5 hours under caustic soda 3% solution to obtain chitin. This was mixed with 45% Deacetylation reaction was performed under heating in a solution, and the solid shape filtered by filtration was vacuum-dried to prepare chitosan having a number average molecular weight of 150,000.
실시예 1: 굼벵이를 함유하는 다이어트 음료의 제조Example 1: Preparation of a diet drink containing slugs
상기 제조예 2로부터 제조된 혼합 추출액 전체 중량에 대해 3 중량%의 키토산을 혼합하여 질소 분위기 및 90 ℃ 조건에서 4000 RPM으로 교반하여, 상기 혼합 추출액이 키토산에 의해 표면코팅되어 집적화(self-aggregation)된 상태의 다이어트 음료를 제조하였다.
3 wt% of chitosan was mixed with the total weight of the mixed extract prepared in Preparation Example 2, and the mixture was stirred at 4000 rpm under a nitrogen atmosphere and a temperature of 90 ° C. The mixed extract was surface-coated with chitosan to self- To prepare a diet drink.
실시예 2Example 2
상기 실시예 1과 동일하게 수행하되, 상기 제조예 2로부터 제조된 혼합 추출액 전체 중량에 대해 3 중량%의 키토산을 80 ℃의 질소 분위기에서 4000 RPM으로 교반 혼합하여 다이어트 음료를 제조하였다.
3% by weight of chitosan was mixed with stirring at 4000 rpm in a nitrogen atmosphere at 80 ° C with respect to the total weight of the mixed extract prepared in Preparation Example 2 to prepare a diet drink.
실시예 3Example 3
상기 실시예 1과 동일하게 수행하되, 상기 제조예 2로부터 제조된 혼합 추출액 전체 중량에 대해 3 중량%의 키토산을 100 ℃의 질소 분위기에서 4000 RPM으로 교반 혼합하여 다이어트 음료를 제조하였다.
3% by weight of chitosan was mixed with stirring at 4000 rpm in a nitrogen atmosphere at 100 ° C with respect to the total weight of the mixed extract prepared in Preparation Example 2 to prepare a diet drink.
실시예 4Example 4
상기 실시예 1과 동일하게 수행하되, 상기 제조예 2로부터 제조된 혼합 추출액 전체 중량에 대해 3 중량%의 키토산을 90 ℃의 질소 분위기에서 3500 RPM으로 교반 혼합하여 다이어트 음료를 제조하였다.
3% by weight of chitosan was mixed with stirring at 3500 rpm in a nitrogen atmosphere at 90 ° C to the total weight of the mixed extract solution prepared in Preparation Example 2 to prepare a diet drink.
실시예 4Example 4
상기 실시예 1과 동일하게 수행하되, 상기 제조예 2로부터 제조된 혼합 추출액 전체 중량에 대해 3 중량%의 키토산을 90 ℃의 질소 분위기에서 4500 RPM으로 교반 혼합하여 다이어트 음료를 제조하였다.
3% by weight of chitosan was mixed with stirring at 4500 rpm in a nitrogen atmosphere at 90 ° C to the total weight of the mixed extract prepared in Preparation Example 2 to prepare a diet drink.
비교예 1Comparative Example 1
상기 실시예 1과 동일하게 수행하되, 상기 제조예 2로부터 제조된 혼합 추출액 전체 중량에 대해 3 중량%의 키토산을 실온의 공기 중에서 4000 RPM으로 교반 혼합하여 다이어트 음료를 제조하였다.
3% by weight of chitosan was mixed with stirring at 4000 rpm in air at room temperature to prepare a diet drink, in the same manner as in Example 1, except that the total weight of the mixed extract prepared in Preparation Example 2 was mixed.
비교예 2Comparative Example 2
상기 실시예 1과 동일하게 수행하되, 상기 제조예 2로부터 제조된 혼합 추출액 전체 중량에 대해 3 중량%의 키토산을 90 ℃의 공기 중에서 4000 RPM으로 교반 혼합하여 다이어트 음료를 제조하였다.
3% by weight of chitosan was mixed with stirring at 4000 rpm in air at 90 ° C with respect to the total weight of the mixed extract prepared in Preparation Example 2 to prepare a diet drink.
비교예 3Comparative Example 3
상기 실시예 1과 동일하게 수행하되, 상기 제조예 2로부터 제조된 혼합 추출액 전체 중량에 대해 3 중량%의 키토산을 40 ℃의 질소 분위기에서 4000 RPM으로 교반 혼합하여 다이어트 음료를 제조하였다.
3% by weight of chitosan was mixed with stirring at 4000 rpm in a nitrogen atmosphere at 40 ° C with respect to the total weight of the mixed extract prepared in Preparation Example 2 to prepare a diet drink.
비교예 4Comparative Example 4
상기 실시예 1과 동일하게 수행하되, 상기 제조예 2로부터 제조된 혼합 추출액 전체 중량에 대해 3 중량%의 키토산을 140 ℃의 질소 분위기에서 4000 RPM으로 교반 혼합하여 다이어트 음료를 제조하였다.
3% by weight of chitosan was mixed with stirring at 4000 rpm in a nitrogen atmosphere at 140 ° C to the total weight of the mixed extract prepared in Preparation Example 2 to prepare a diet drink.
비교예 5Comparative Example 5
상기 실시예 1과 동일하게 수행하되, 상기 제조예 2로부터 제조된 혼합 추출액 전체 중량에 대해 3 중량%의 키토산을 90 ℃의 질소 분위기에서 2500 RPM으로 교반 혼합하여 다이어트 음료를 제조하였다.
3% by weight of chitosan was mixed with stirring at 2500 rpm in a nitrogen atmosphere at 90 ° C with respect to the total weight of the mixed extract prepared in Preparation Example 2 to prepare a diet drink.
비교예 6Comparative Example 6
상기 실시예 1과 동일하게 수행하되, 상기 제조예 2로부터 제조된 혼합 추출액 전체 중량에 대해 3 중량%의 키토산을 90 ℃의 질소 분위기에서 5500 RPM으로 교반 혼합하여 다이어트 음료를 제조하였다.
3% by weight of chitosan was mixed with stirring at 5500 rpm in a nitrogen atmosphere at 90 ° C with respect to the total weight of the mixed extract prepared in Preparation Example 2 to prepare a diet drink.
실험예 1: 세포독성 실험Experimental Example 1: Cytotoxicity test
상기 제조예 2로부터 제조된 혼합 추출액, 실시예 1 내지 5 및 비교예 1 내지 6으로부터 제조된 다이어트 음료를 PC-12 세포주를 사용하여 그 세포독성을 MTS assay로 측정하였다. 양성대조물로는 아지드화나트륨(NaN3, sodiumazide)을 사용하여 37 ℃, 5% CO2 조건에서 48 시간 배양하였다. 상기 시료를 각각 0.1, 0.05, 0.001, 0.005 중량% 에 각각 아지드화나트륨을 0.2 ml씩 가하여 490 nm에서 흡광도를 측정하였다. The cytotoxicity of the diet drinks prepared from the mixed extracts prepared in Preparation Example 2, Examples 1 to 5 and Comparative Examples 1 to 6 was measured by MTS assay using PC-12 cell line. As a positive control, sodium azide (NaN 3 , sodium azide) was used for 48 hours at 37 ° C and 5% CO 2 . Absorbance was measured at 490 nm by adding 0.2 ml of sodium azide to each of the above samples at 0.1, 0.05, 0.001 and 0.005% by weight, respectively.
그 결과, 상기 제조예 2로부터 제조된 혼합 추출액, 실시예 1 내지 5 및 비교예 1 내지 6의 상기 어느 농도에서도 세포독성이 없었음을 확인하였다.
As a result, it was confirmed that no cytotoxicity was observed at any of the concentrations of the mixed extract prepared in Preparation Example 2, Examples 1 to 5, and Comparative Examples 1 to 6.
실험예 2: 생체 이용율 실험Experimental Example 2: Bioavailability experiment
상기 제조예 2로부터 제조된 혼합 추출액, 실시예 1 내지 5 및 비교예 1 내지 6으로부터 제조된 다이어트 음료를 각 1 중량% 용액으로 제조한 후 형광 표적물질인 FITC를 부착시키고 실험동물 200 g의 정상 쥐의 꼬리 정맥에 주사 후 쥐의 간, 혈액 및 뇨에서 48 시간 뒤의 생체 이용율을 비교하여 하기 표 1에 나타내었다. 생체 이용율은 각 시간에 배출된 FITC의 질량을 투입된 FITC의 질량으로 나눈 백분율로 계산하였다. The dietary beverages prepared from the mixed extracts prepared in Preparation Example 2, Examples 1 to 5 and Comparative Examples 1 to 6 were prepared as 1 wt% solutions, and FITC, a fluorescent target material, The bioavailability after 48 hours in rat liver, blood and urine after injection into the tail vein of rats is shown in Table 1 below. Bioavailability was calculated as the percentage of FITC released at each time divided by the mass of injected FITC.
하기 표 1을 참조하면, 제조예 2로부터 제조된 혼합 추출액은 48 시간 째에 68.1%만이 간에서 흡수되었으며, 77.0%만이 혈액을 통해 뇨로 배출되었다. 실시예 1 내지 5의 시료는 48 시간 째에 84% 이상 간에서 흡수되었으며, 95% 이상 혈액을 통해 뇨로 배출되었다. 그러나 키토산을 교반하여 단순 혼합한 비교예 1의 시료는 48 시간째 뇨로 배출되는 비율이 실시예들에 비해 10% 이상 낮았고, 키토산을 공기 중에서 교반한 비교예 2, 60 내지 120 ℃를 벗어나는 온도 범위에서 혼합한 비교예 3 내지 4 및 3000 내지 5000 RPM을 벗어나는 교반속도 범위에서 혼합한 비교예 5 내지 6에서도 비교예 1 보다는 높지만 실시예들에 비해서 5 내지 6% 정도 낮은 생체 이용율을 나타냄을 확인할 수 있다.Referring to the following Table 1, only 68.1% of the mixed extract prepared in Preparation Example 2 was absorbed in the liver at 48 hours, and only 77.0% was excreted into the urine through blood. The samples of Examples 1 to 5 were absorbed in the liver by 84% or more at 48 hours, and were discharged into the urine through the blood of 95% or more. However, the sample of Comparative Example 1 in which chitosan was stirred by mixing was lower than that of Examples in the rate of discharging into urine for 48 hours. Comparative Example 2 in which chitosan was stirred in air, temperature range exceeding 60 to 120 占 폚 Of Comparative Examples 3 to 4 and Comparative Examples 5 to 6 mixed at a stirring speed range exceeding 3000 to 5000 RPM showed higher bioavailability than Comparative Example 1 but about 5 to 6% have.
실험예 3: 효율성 실험Experimental Example 3: Efficiency Experiment
실험동물로 ICR 마우스를 이용하여, 상기 제조예 2로부터 제조된 혼합 추출액, 실시예 1 내지 5 및 비교예 1 내지 6으로부터 제조된 다이어트 음료를 재료로 한 시험대조군과 정상군을 식이 급여하며 사육 비교하였다.As a test animal, ICR mice were used for dietary beverage prepared from the mixed extract prepared in Preparation Example 2, Examples 1 to 5 and Comparative Examples 1 to 6, Respectively.
본 실험에서 기본 식이는 AIN-76을 기본으로 단백질급원은 카제인(Japan), 탄수화물급원은 옥수수전분(제일제당), 지방급원으로 옥수수유(대상)을 사용한 정상군과 시험대조군을 비교하는 방식으로 진행하였다. 본 실험에 사용한 다이어트 음료는 매일 일정시간에 1 ml씩 경구 급여하였으며 식이와 식수는 임의로 자유롭게 섭취하도록 하였다. 시험동물 사육환경은 항온(20±2℃), 항습(50±5%)하고 12 시간 광주기로 일정 조건을 유지하면서 폴리카보네이트 케이지에서 2 마리씩 분리하여 사육하였다. 동물에서 콜레스테롤은 혈류를 따라 순환하며 몇몇 기관에서 합성되며 혈류 내에서 콜레스테롤 수치가 크면 동맥경화의 주요 원인이 되므로 분석항목은 (1) 체중변화 및 식이섭취량, (2) 혈중 콜레스테롤 및 중성지질을 측정하는 것으로 진행하였다. In this experiment, the basic diet was based on AIN-76, the protein source was casein (Japan), the carbohydrate source was corn starch (Cheiljedang), and the fat source was corn oil (subject) . The dietary beverage used in this experiment was orally fed at a constant daily dose of 1 ml, and the diets and drinking water were freely taken. The animals were kept at constant temperature (20 ± 2 ℃), humidity (50 ± 5%) and maintained in a light condition for 12 hours. Two animals were kept in a polycarbonate cage. Cholesterol in the animal circulates along the bloodstream and is synthesized in several organs. When the cholesterol level in the bloodstream is high, it is a major cause of arteriosclerosis. The analysis items are (1) weight change and dietary intake, (2) blood cholesterol and neutral lipid .
사육이 끝난 실험동물은 12 시간 절식시킨 후 에테르(Ether)를 흡입시켜 마취시킨 다음 복부 하대정맥으로부터 채혈하였으며, 헤파린을 처리하여 원심분리(15 mins, 3,000 RPM)로 혈장을 분리하여 지질함량을 측정하였다.After the breeding, the animal was fasted for 12 hours, then the ether was inhaled and the blood was collected from the abdominal subclavian vein. The plasma was separated by centrifugation (15 mins, 3,000 rpm) to measure the lipid content Respectively.
각 실험동물의 내장(간, 부고환, 신장)을 혈액채취 후 즉시 적출하여 PBS(Phosphate Buffered saline) 용액으로 수차례 헹군 후 표면 수분을 제거하여 비교 정량하였다. 혈장 중성지질은 McGowan 등(1983)의 효소법을 이용한 발색방식의 중성지방 측정용 시액(Asan kit)를 사용하여 550 nm에서 흡광도를 측정하였으며, 혈장 총 콜레스테롤은 Allain 등(1974)의 효소법을 응용한 총콜레스테롤 측정용 시액(Asan kit)를 사용하여 발색처리하여 500 nm에서 흡광도를 측정하여 이를 콜레스테롤 표준곡선과 비교 정량하는 방식으로 하였으며, 장기의 지질은 Folch 등(1957)의 방법으로 잘게 자른 후 2 ml, Chloroform: Methyl alcohol 2:1 용액하에서 추출하여 중성지질, 콜레스테롤은 혈장에서와 동일 방법으로 정량하였다. 각 항목은 통계처리하여 평균값으로 하였다.
The internal organs (liver, epididymal, kidney) of each animal were immediately removed after blood sampling, rinsed several times with PBS (phosphate buffered saline) solution, and surface moisture was removed and compared. Plasma neutral lipids were measured by absorbance at 550 nm using the Asan kit for color measurement using enzymatic method of McGowan et al. (1983). Plasma total cholesterol was determined by the enzyme method of Allain et al. (1974) The asan kit was used to measure the absorbance at 500 nm. The absorbance was compared with the cholesterol standard curve. The lipid of the organs was cut by the method of Folch et al. (1957) ml, Chloroform: Methyl alcohol 2: 1, and neutral lipids and cholesterol were quantified in the same manner as in plasma. Each item was statistically treated as an average value.
(1) 체중변화(1) weight change
실험동물의 체중변화 및 식이섭취량을 하기 표 2 및 3에 각각 나타내었다. The body weight change and the dietary intake of the experimental animals are shown in Tables 2 and 3, respectively.
하기 표 2를 참조하면, 실시예 1 내지 5로부터 제조된 다이어트 음료를 경구 급여한 실험동물의 경우 실험전에 비하여 체중이 유사 또는 저하되었고, 반면 제조예 2로부터 제조된 혼합 추출액, 비교예 1 내지 6으로부터 제조된 다이어트 음료를 경구 급여한 실험동물 및 정상군의 경우 실험전에 비하여 체중이 증가했음을 확인할 수 있다.The results are shown in Table 2 below. In the case of the experimental animals fed orally with diet drinks prepared in Examples 1 to 5, the body weight was similar or decreased compared to that before the experiment, while the mixed extracts prepared in Preparation Example 2, The weight of the experimental animals and the normal group fed orally with the diet drinks prepared from the control group were increased compared to those before the experiment.
하기 표 3을 참조하면, 제조예 2로부터 제조된 혼합 추출액, 실시예 1 내지 5 및 비교예 1 내지 6으로부터 제조된 다이어트 음료를 경구 급여한 실험동물 및 정상군의 식이섭취량은 모두 유사한 것으로 확인하였다.Referring to the following Table 3, it was confirmed that the dietary intake of the mixed extract prepared in Preparation Example 2, the dietary beverage prepared in Examples 1 to 5 and Comparative Examples 1 to 6, .
이를 통하여 모든 실험동물의 식이 섭취량이 유사함에도 불구하고, 실시예 1 내지 5의 다이어트 음료를 섭취한 실험동물의 체중이 모두 증가하지 않고, 실험 전과 유사하거나 실험전에 비하여 감소하여 다이어트 음료로서 활용 가능함을 확인하였다.Although the dietary intake of all the experimental animals is similar, the weight of the experimental animals consuming the diet drinks of Examples 1 to 5 is not increased, and they are similar to those before the experiment, Respectively.
(2) 혈중 콜레스테롤 및 중성지질(2) Blood cholesterol and neutral lipids
실험동물의 혈장 중성지질, 혈장 콜레스테롤, 부고환 중성지질, 신장 조직의 중성지질 및 간조직에서의 콜레스테롤을 하기 표 4 내지 8에 나타내었다.Plasma neutral lipid, plasma cholesterol, epididymal neutral lipid, neutral lipid in kidney tissue and cholesterol in liver tissue of experimental animals are shown in Tables 4 to 8 below.
하기 표 4를 참조하면, 실시예 1 내지 5의 다이어트 음료를 섭취한 시험대조군은 실험전에 비해 혈장 중성지질이 현저히 감소한 반면, 제조예 2로부터 제조된 혼합 추출액 및 비교예 1 내지 6의 다이어트 음료를 섭취한 시험대조군은 유의적인 변화가 나타나지 않았으며, 정상군의 경우 오히려 혈장 중성지질이 증가한 것을 확인할 수 있다.The results are shown in Table 4. Referring to Table 4, in the test control group in which the diet drinks of Examples 1 to 5 were consumed, the plasma neutral lipid was remarkably decreased compared to the experiment, while the mixed extract prepared in Preparation Example 2 and the diet drinks of Comparative Examples 1 to 6 There was no significant change in the intake of the test group, and the plasma neutral lipid level was increased in the normal group.
하기 표 5를 참조하면, 실시예 1 내지 5의 다이어트 음료를 섭취한 시험대조군은 실험전에 비해 혈장 콜레스테롤이 현저히 감소한 반면, 제조예 2, 비교예 1 내지 6 및 정상군은 유의적인 변화가 나타나지 않았음을 확인할 수 있다.Referring to the following Table 5, in the test control group in which the diet drinks of Examples 1 to 5 were consumed, the plasma cholesterol was remarkably decreased compared with that before the experiment, while the production group 2, the comparative examples 1 to 6 and the normal group showed no significant change You can see the sound.
표 6을 참조하면, 실시예 1 내지 5의 다이어트 음료를 섭취한 시험대조군은 실험전에 비해 부고환의 중성지질이 현저히 감소한 반면, 제조예 2 및 비교예 1 내지 6은 유의적인 변화가 나타나지 않았으며, 정상군은 오히여 부고환의 중성지질이 증가하였음을 확인할 수 있다.As shown in Table 6, the neutral lipids of the epididymis were markedly decreased in the test control group in which the diet drinks of Examples 1 to 5 were consumed, whereas the production of the diet drinks of Comparative Examples 1 to 6 was not significantly changed, In the normal group, it was confirmed that the neutral lipid of the hypothalamus increased.
표 7을 참조하면, 실시예 1 내지 5의 다이어트 음료를 섭취한 시험대조군은 실험전에 비해 신장 조직의 중성지질이 현저히 감소한 반면, 제조예 2 및 비교예 1 내지 6은 유의적인 변화가 나타나지 않았으며, 정상군은 신장 조직의 중성지질이 증가했음을 확인할 수 있다.Referring to Table 7, in the test control group in which the diet drinks of Examples 1 to 5 were consumed, the neutral lipid of the kidney tissue was remarkably decreased compared to that before the experiment, while the production of Example 2 and Comparative Examples 1 to 6 showed no significant change , And the normal group showed an increase in the neutral lipid of kidney tissue.
표 8을 참조하면, 실시예 1 내지 5의 다이어트 음료를 섭취한 시험대조군은 실험전에 비해 간조직의 콜레스테롤이 현저히 감소한 반면, 제조예 2, 비교예 1 내지 6 및 정상군은 유의적인 변화가 나타나지 않았음을 확인할 수 있다.Referring to Table 8, in the test control group in which the diet drinks of Examples 1 to 5 were consumed, the cholesterol of the liver tissue was remarkably decreased compared to that before the experiment, while the production group 2, the comparative examples 1 to 6 and the normal group showed significant changes .
상기 결과를 통하여, 본 발명에 따른 실시예들을 통해 제조된 다이어트 음료는 부고환 및 신장 조직에서 중성지질의 양의 감소현상을 확인할 수 있어 내장지방 개선효과가 있음을 확인할 수 있었으며, 특히 간조직에서 콜레스테롤 수치가 개선되는 것을 확인할 수 있는 등 전반적으로 지방과 콜레스테롤을 개선시키는 특징을 확인하였다. From the above results, it can be seen that the diet drinks manufactured through the examples according to the present invention can reduce the amount of the neutral lipids in the epididymal and kidney tissues, and thus can improve the visceral fat. In particular, the cholesterol And improvement of fat and cholesterol.
실험예 4: 항균활성 실험Experimental Example 4: Antibacterial activity test
상기 실시예 1 및 비교예 1 내지 6으로부터 제조된 다이어트 음료를 1 중량% 용액으로 희석하여 Streptococcus mutans 및 Escherichia coli ATCC8739에 대하여 MIC((minimal inhibitory concentration: 미생물의 생육을 저해하는데 필요한 최저 농도)를 측정하여 하기 표 9에 나타내었다.The diet drinks prepared in Example 1 and Comparative Examples 1 to 6 were diluted with a 1 wt% solution to measure the minimum inhibitory concentration (MIC) required for inhibiting the growth of microorganisms against Streptococcus mutans and Escherichia coli ATCC 8739 Are shown in Table 9 below.
하기 표 9를 참조하면, 실시예 1은 비교예 1 내지 6에 비하여 스트렙토코커스 뮤탄스와 대장균에 대한 MIX가 1/5 내지 1/6 에 불과하여 항균 활성이 현저히 우수함을 확인하였다.Referring to Table 9, it was confirmed that the MIX for Streptococcus mutans and E. coli was 1/5 to 1/6 that of Comparative Example 1 to 6, and that the antibacterial activity was remarkably excellent.
실험예 5: 관능검사Experimental Example 5: Sensory evaluation
상기 제조예 2로부터 제조된 혼합 추출액, 실시예 1 내지 5 및 비교예 1 내지 6으로부터 제조된 다이어트 음료에 대한 관능검사를 실시하였다. The dietary drinks prepared from the mixed extracts prepared in Preparation Example 2, Examples 1 to 5 and Comparative Examples 1 to 6 were subjected to sensory evaluation.
식품관련 분야에서 3 년 이상의 관능검사 경력을 지닌 패널 20 명(남여 각각 10 명)으로 하여금 실시예 및 비교예의 굼벵이를 함유하는 다이어트 음료를 시음하게 한 후 관능검사를 하여 9 점 척도법(정도가 클수록 9점에 가까움)으로 측정하였으며, 이를 하기 표 10에 나타내었다.20 panelists (10 males and 10 females) with more than three years of sensory experience in the food-related field tasted the diet drinks containing the slugs of Examples and Comparative Examples, followed by sensory evaluation, and the 9-point scale method 9). The results are shown in Table 10 below.
하기 표 10을 참조하면, 실시예 1 내지 5로부터 제조된 굼벵이를 함유하는 다이어트 음료는 제조예 2 및 비교예 1 내지 6에 비하여 전체적인 향, 전체적인 맛, 목넘김, 후미 및 종합적인 기호도 모두 우수하며, 굼벵이 특유의 역겨운 냄새 및 맛이 상당히 감소한 것을 확인할 수 있다.
Referring to the following Table 10, the diet drinks containing slugs prepared in Examples 1 to 5 are superior to those of Preparation Example 2 and Comparative Examples 1 to 6 in overall flavor, overall taste, flavor, It can be confirmed that the unpleasant odor and taste specific to the slugs are significantly reduced.
-전체적인 향, 전체적인 맛, 목넘김, 후미 및 종합적인 기호도: 1점= 매우 나쁘다, 9점= 매우 좋다- Overall incense, overall taste, hump, cusp and overall preference: 1 point = very bad, 9 points = very good
-굼벵이 특유의 역겨운 냄새 및 맛: 1점= 매우 약하다, 9점= 매우 강하다- Unpleasant smell and taste of slugs: 1 point = very weak, 9 points = very strong
Claims (7)
상기 혼합 추출액 전체 중량에 대해 0.5 내지 10 중량%의 키토산;을 포함하는 것을 특징으로 하는 굼벵이를 함유하는 다이어트 음료.The extract of Liliaceae extracts in an amount of 5 to 30% by weight, the extract of Lilac extract in an amount of 3 to 10% by weight and the extract of Liliaceae in an amount of 10 to 50% by weight, an old pumpkin extract in an amount of 5 to 30% A mixed extract containing 5 to 20% by weight of Angelica gigas Nakai extract; And
And 0.5 to 10% by weight of chitosan based on the total weight of the mixed extract.
고콜레스테롤혈증, 고지혈증 또는 이들의 합병증으로서 관상 동맥 질환, 협심증, 경동맥 질환, 뇌졸증, 뇌동맥경화증, 콜레스테롤 담석, 제Ⅱ형 당뇨병, 지질 이상증, 비만 및 만성 염증성 장애로 이루어진 군으로부터 선택되는 질환의 개선 또는 예방이 가능한 것을 특징으로 하는 굼벵이를 함유하는 다이어트 음료.The method according to claim 1,
Improvement of a disease selected from the group consisting of hypercholesterolemia, hyperlipidemia or a complication thereof selected from the group consisting of coronary artery disease, angina pectoris, carotid artery disease, stroke, cerebral arterial sclerosis, cholesterol gallstone, type II diabetes, lipid disorders, obesity and chronic inflammatory disorders A diet drink containing slugs characterized by being preventable.
(b) 상기 혼합 추출액 전체 중량에 대해 0.5 내지 10 중량%의 키토산을 혼합하여 혼합액을 수득하는 단계;를 포함하는 굼벵이를 함유하는 다이어트 음료의 제조방법.(a) 10 to 50% by weight of an extract of slugs, 5 to 30% by weight of an old pumpkin extract, 3 to 20% by weight of a ginger extract, 5 to 20% by weight of an extract of Baekbokryeong, 5 to 30% And 5 to 20% by weight of Angelica gigas Nakai extract to obtain a mixed extract; And
(b) mixing 0.5 to 10% by weight of chitosan with respect to the total weight of the mixed extract to obtain a mixed solution.
상기 굼벵이 추출액은, 고압멸균 및 동결건조된 굼벵이에 물을 6 내지 15 배 중량으로 혼합한 혼합물을 80 내지 150 ℃에서 8 내지 20 시간 동안 증류 추출하여 제조된 것을 특징으로 하는 굼벵이를 함유하는 다이어트 음료의 제조방법.The method of claim 3,
The slug extract is prepared by distilling a mixture obtained by mixing 6 to 15 times by weight of water with high pressure sterilized and freeze dried slugs by distillation extraction at 80 to 150 DEG C for 8 to 20 hours. ≪ / RTI >
상기 늙은 호박 추출액, 구기자 추출액, 백복령 추출액, 차전자 추출액, 칡 추출액 및 당귀 추출액 각각은, 늙은 호박, 구기자, 백복령, 차전자, 칡 또는 당귀에 물을 25 내지 50 배 중량으로 혼합한 혼합물을 80 내지 150 ℃에서 8 내지 20 시간 동안 증류 추출하여 제조된 것을 특징으로 하는 굼벵이를 함유하는 다이어트 음료의 제조방법.The method of claim 3,
Each of the old pumpkin extract, Gugija extract, Baekbokryei extract, tea extract, chrysanthemum extract and Angelica gigantum extract was mixed with 25 to 50 times by weight of water to old pumpkin, gugija, To 150 DEG C for 8 to 20 hours.
상기 (b) 단계는 질소 분위기 및 60 내지 120 ℃ 조건에서 3000 내지 5000 RPM으로 교반하여 수행되는 것을 특징으로 하는 굼벵이를 함유하는 다이어트 음료의 제조방법.The method of claim 3,
Wherein the step (b) is performed by stirring at 3000 to 5000 RPM under a nitrogen atmosphere and a temperature of 60 to 120 占 폚.
(c) 상기 혼합액 및 한천을 혼합하여 겔상화 한 후 살균하는 단계;를 더욱 포함하는 것을 특징으로 하는 굼벵이를 함유하는 다이어트 음료의 제조방법.The method of claim 3,
(c) mixing the mixture and agar to gel, and then sterilizing the slurry.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160147988A KR101888549B1 (en) | 2016-11-08 | 2016-11-08 | Diet beverage comprising white grup and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160147988A KR101888549B1 (en) | 2016-11-08 | 2016-11-08 | Diet beverage comprising white grup and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20180051095A true KR20180051095A (en) | 2018-05-16 |
KR101888549B1 KR101888549B1 (en) | 2018-08-14 |
Family
ID=62452029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160147988A KR101888549B1 (en) | 2016-11-08 | 2016-11-08 | Diet beverage comprising white grup and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101888549B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102000427B1 (en) | 2019-05-10 | 2019-07-15 | 조대호 | Method of manufacturing grub extract |
KR20200056832A (en) * | 2018-11-15 | 2020-05-25 | (주)화인에프티 | Composition for Anti-diabetic comprising Hydrorized Extract of Glub |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102206455B1 (en) | 2020-03-20 | 2021-01-22 | 농업회사법인 삼우바이오팜 (주) | Grub pill and manufacturing method of the same |
KR102490409B1 (en) | 2020-07-23 | 2023-01-25 | 에이치엠오건강드림영농조합법인 | Health food composition with significantly improved blood sugar lowering and diabetes prevention effect, and slug breeding method therefor |
KR102654473B1 (en) | 2023-09-14 | 2024-04-04 | 주식회사 한미양행 | A method for producing beverage using edible insects |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010086170A (en) * | 2000-10-23 | 2001-09-10 | 강창환 | The composites of raw-type tea with anti-obese function |
US6521268B2 (en) | 2001-02-08 | 2003-02-18 | Jakwang Co., Ltd. | Antibacterial and anti-inflammatory compositions with Inula helenium L. extract and water soluble chitosan |
KR20050013370A (en) * | 2003-07-28 | 2005-02-04 | 김영찬 | Fatness remedy composition using Chinese medicine |
KR100735675B1 (en) | 2004-10-16 | 2007-07-04 | 유향자 | The Processing Method to Improve Efficacy of Collagen by Low-Molecularization and Hydrophilicity, and Collagen Thereof |
KR101359507B1 (en) | 2012-06-20 | 2014-02-12 | 대한민국 | Method for manufacturing edible Protaetia brevitarsis powder |
KR101382400B1 (en) | 2012-06-20 | 2014-04-10 | 대한민국 | Composition comprising Protaetia brevitarsis for preventing and treating Inflammatory Disorder |
KR20140147948A (en) * | 2013-06-20 | 2014-12-31 | 대한민국(농촌진흥청장) | Manufacturing Method for Allomyrina dichotoma extract having anti-Obesity effect and Anti-Obesity Composition Containing the same |
KR101491771B1 (en) | 2013-01-03 | 2015-02-16 | 대한민국 | Preparing method for protaetia brevitarsis suspension and anti-obesity composition containing the same |
KR101564668B1 (en) | 2014-08-08 | 2015-10-30 | 유향자 | Preparation method for chitosan fermented with herb and its use |
KR101659927B1 (en) | 2014-08-08 | 2016-09-26 | 유향자 | Enhancing method for pharmaceutical effect of herb, preparation method for fermented chitosan for immune stimulating and its use |
-
2016
- 2016-11-08 KR KR1020160147988A patent/KR101888549B1/en active IP Right Grant
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010086170A (en) * | 2000-10-23 | 2001-09-10 | 강창환 | The composites of raw-type tea with anti-obese function |
US6521268B2 (en) | 2001-02-08 | 2003-02-18 | Jakwang Co., Ltd. | Antibacterial and anti-inflammatory compositions with Inula helenium L. extract and water soluble chitosan |
KR20050013370A (en) * | 2003-07-28 | 2005-02-04 | 김영찬 | Fatness remedy composition using Chinese medicine |
KR100735675B1 (en) | 2004-10-16 | 2007-07-04 | 유향자 | The Processing Method to Improve Efficacy of Collagen by Low-Molecularization and Hydrophilicity, and Collagen Thereof |
KR101359507B1 (en) | 2012-06-20 | 2014-02-12 | 대한민국 | Method for manufacturing edible Protaetia brevitarsis powder |
KR101382400B1 (en) | 2012-06-20 | 2014-04-10 | 대한민국 | Composition comprising Protaetia brevitarsis for preventing and treating Inflammatory Disorder |
KR101491771B1 (en) | 2013-01-03 | 2015-02-16 | 대한민국 | Preparing method for protaetia brevitarsis suspension and anti-obesity composition containing the same |
KR20140147948A (en) * | 2013-06-20 | 2014-12-31 | 대한민국(농촌진흥청장) | Manufacturing Method for Allomyrina dichotoma extract having anti-Obesity effect and Anti-Obesity Composition Containing the same |
KR101564668B1 (en) | 2014-08-08 | 2015-10-30 | 유향자 | Preparation method for chitosan fermented with herb and its use |
KR101659927B1 (en) | 2014-08-08 | 2016-09-26 | 유향자 | Enhancing method for pharmaceutical effect of herb, preparation method for fermented chitosan for immune stimulating and its use |
Non-Patent Citations (6)
Title |
---|
1. Rolls B.J et al., Obes. Res. 6: 1-11, 1988 |
2. Hansen D.L. et al., Am. J. Clin. Nutr. 68: 1180-1186, 1998 |
3. 중소기업기술혁신개발사업과제: 연구책임자 유향자 "대체의약소재개발(Netraceuticals peptide 결합 glucan 천연 면역강화소재의 개발"- (2001. 5 ~ 2002. 4) |
4. SangBong Seo, "A Study on the Development of Novel Water-soluble Chitosan and Its Applications to Environment, Fine Chemicals and Medical Use" Tokyo Institute of Technology (2003) |
5. Hyung-Min Kim, SangBong Seo et.al"Nitric oxide production by high molecular weight water-soluble chitosan via nuclear factor-kB activation" International Journal of Immunopharmacology 22 (2000) 923-933 |
박영숙. 약용식물의 증류 추출물을 이용한 기능성 음료 개발에 관한 연구. 동아시아식생활학회. 17(3): pp.384~392 (2007).* * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200056832A (en) * | 2018-11-15 | 2020-05-25 | (주)화인에프티 | Composition for Anti-diabetic comprising Hydrorized Extract of Glub |
KR102000427B1 (en) | 2019-05-10 | 2019-07-15 | 조대호 | Method of manufacturing grub extract |
Also Published As
Publication number | Publication date |
---|---|
KR101888549B1 (en) | 2018-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Maan et al. | The therapeutic properties and applications of Aloe vera: A review | |
KR101888549B1 (en) | Diet beverage comprising white grup and preparation method thereof | |
Pandey et al. | Aloe Vera: A Systematic Review of its Industrial and Ethno-Medicinal Efficacy. | |
US20200368301A1 (en) | Novel Composition to Improve Gut Health and Animal Performance and Methods of Making the Same | |
KR102038650B1 (en) | Composite of Natural soap for skin cure and Method of manufacturing thereof | |
KR102020586B1 (en) | Healthy foods for elderly comprising animal and plant extracts and process for preparation thereof | |
CN111374297A (en) | Compound salt and preparation method thereof | |
KR20150040392A (en) | undiluted stevia liquid and the berages, and its manufacturing method | |
CN104247913A (en) | Health rice vermicelli | |
KR101598395B1 (en) | Method for producing wild plants Kimchi comprising Houttuynia cordata, Saururus chinensis and Momordica charantia | |
JPH0767576A (en) | Healthy edible material of mycelium | |
KR20200023053A (en) | Powder type multiple food supplement comprising beta glucan powder, chitosan powder, acerola extract powder, ganoderma lucidum fruit body powder, grifola frondosa powder, lentinus edodes mycelium powder, lycium chinense powder, aloe powder, angelica gigas extract powder and ginseng extract powder | |
CN104855485A (en) | Sweet potato-pumpkin pie capable of relaxing bowels and having weight-losing effect and preparation method of sweet potato-pumpkin pie | |
CN107494938A (en) | A kind of Chinese herbal medicine mixed feed for improving beef cattle immunity and preparation method thereof | |
JP2006232763A (en) | Bamboo grass extract-containing composition, cosmetic and food and drink containing the same | |
KR20170003153A (en) | A composition for the prevention and treatment of respiratory organ disease comprising the fractions of Asparagus cochinchinensis as an active ingredien | |
CN109939049A (en) | Pure plant antibiotic health care wet tissue formula and preparation method thereof | |
KR20160062390A (en) | mixing method of freeze-drying dried sea cucumber and source using pouch | |
CN109620858A (en) | The integration of drinking and medicinal herbs preparation for preventing and treating diabetes | |
RU2751230C1 (en) | Functional product | |
KR102389839B1 (en) | Health supplement composition for improving bronchial function including natural extracts | |
RU2781113C1 (en) | Composition of ingredients for non-alcoholic beverages and foods | |
CN107596247A (en) | A kind of anaesthetic and its manufacturing process for treating tuberculosis | |
Bahndral et al. | Sources of plant based gums and their utilization in herbal drink: A Review | |
CN107080257A (en) | A kind of preparation of liver protecting raspberry lozenge |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |